Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 double-masked, placebo-controlled study of danicopan in geographic atrophy secondary to AMD
jRCT2051220074Phase 2Active, not recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jun 2022
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of danicopan in age-related macular degeneration (AMD) (4 arms), sponsored by Alexion Pharmaceuticals. Primary endpoint: Change from baseline to Week 52 in the square root of total GA lesion area. Started Jun 2022; status: active, not recruiting.
02
Drugs
danicopan
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on jRCT2051220074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051220074.